New test could predict who benefits from CAR t therapy
NCT ID NCT07472972
First seen Mar 26, 2026 · Last updated Apr 30, 2026 · Updated 2 times
Summary
This study aims to create a tool that combines blood tests, scans, and fitness checks to predict which lymphoma patients will respond to CAR T cell therapy. About 50 adults with relapsed or hard-to-treat B-cell lymphoma will participate. The main goal is to see if the tool can be completed successfully, not to directly treat the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Universityhospital Zurich, Department of Medical Oncology and Hematology
RECRUITINGZurich, Canton of Zurich, 8091, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.